knowledge -WSS

knowledge

author：explore 2025-09-27 16:35:26 - browse：33242

the U.S. Medicare Handbook is photographed in Washington. — Pablo Martinez Monsivais/AP

Roughly 33.4 million adults older than 65 and people with disabilities were enrolled in a Medicare Advantage plan as the calendar flipped to 2024 — another year of steady, albeit slower, growth for the taxpayer-funded program.

Enrollment increased 7.1% year over year, which would make this year’s annual growth rate identical to last year’s, according to new federal Medicare Advantage enrollment data analyzed by STAT.

The data reinforce how America’s Medicare program continues to shift toward a more privatized version that has not saved any money for taxpayers, has been linked to inappropriate coding practices, and has restricted care for older and vulnerable patients. And even though the federal government made several changes to Medicare Advantage for 2024 — changes that were vehemently opposed by the health insurance industry — the program’s growth has not been stunted, nor did insurers dramatically slash their offerings.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Pushing for an NIH office for post

hotspot

WSS

Medicare Advantage proposed rates disappoint insurers

The Readout: Gilead, Bernie Sanders, and other pharma news

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Biden report: The neurospychology of memory and aging

To avoid data mishandling cases, universities eye AI and other tools

BioAge raises $170M for combination therapy with Zepbound

hotspot

knowledge

hotspot

Psychedelics group wrestles with new pharma identity

HHS secretary Becerra pressed on Change HealthCare cyberattack

Peter Hotez and the public health issue of online harassment

Why scientists need input from humanists on sensitive research

Novavax promises a turnaround & Lilly roils the obesity market

BioAge raises $170M for combination therapy with Zepbound

Apple is now the first public company to be valued at $3 trillion

Vaccine advisory panel ACIP left half staffed by HHS

Drug repurposing or repositioning? The language matters

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

hotspot

What we’ve learned from the Aduhelm mess

How to save health care price transparency rules

The Readout: Gilead, Bernie Sanders, and other pharma news

HHS secretary Becerra pressed on Change HealthCare cyberattack

WuXi out of biotech trade group, U.S. and China relations to blame

The Readout: Gilead, Bernie Sanders, and other pharma news

hotspot

focus

explore

leisure time